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Abstract     
The Petasis reaction of 6-alkoxy adducts of 1-alkyl-2,3-dicyano-5-arylpyrazinium salts with 
aromatic boronic acids, such as 2-thienylboronic, 2-furanylboronic and 3-thienylboronic acids, or 
their benzo analogs in dichloromethane proceeds smoothly at room temperature with the 
formation of the corresponding 5-aryl-6-hetaryl substituted 1,6-dihydropyrazine derivatives. All 
dihydropyrazines were separated as pure enantiomers by chiral HPLC, and their absolute 
configurations for each pair of enantiomers have been determined by X-ray analysis. Individual 
enantiomers were screened in vitro for their antimycobacterial activities against  Mycobacterium 
tuberculosis H37Rv, avium, terrae and extensively drug-resistant and multi-drug-resistant strains 
isolated from tuberculosis patients in Ural region (Russia). It has been shown that several 
compounds exhibit a good level of antituberculosis activity compared to the reference drugs. 
 
Keywords: Pyrazines, Petasis reaction, antituberculosis activity, extensively drug-resistant and 
multi-drug-resistant tuberculosis  
 
 
Introduction    
 
Tuberculosis is an illness that results from infection with Mycobacterium tuberculosis (MTB). 
Tuberculosis is responsible for millions of human deaths annually, claiming more lives than any 
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other single infectious agent.1-3 Almost one-third to one-half of the world’s population is infected 
with M. tuberculosis and approximately 10% of infected individuals will experience active 
disease at some time in their life.4 Currently, treatment for active Tuberculosis includes at least 6 
months of therapy with the first line drugs, such as isoniazid, rifampicin, pyrazinamide and 
ethambutol.5-7 Failure of patients to complete a full treatment protocol and the outbreak of 
acquired immune deficiency syndrome (AIDS) has resulted in the emergence of multi-drug 
resistance (MDR). Recent estimates show that 10% of all new tuberculosis infections are 
resistant to at least one antituberculosis drug. Subsequently, the World Health Organization 
(WHO) has declared tuberculosis as global public health emergency.8 For multi-drug resistance 
(MDR) and extensively drug resistance (XDR) combinations of the first line drugs and the 
second line drugs, such as aminoglycosides, fluoroquinolones, thioamides, cycloserine and p-
amino salicylic acid are used.9 Since the discovery of rifampicin in 1960, there is no more drugs 
developed to treat tuberculosis. The third line drugs include rifabutin, clarithromicin, linezolid, 
thiacetone, arginine and vitamin D, which are still being developed, have less or unproven 
efficacy and are very expensive.10 MTB have the cell with a high lipid content, thus resulting in a 
high degree of lipophilicity and resistance to alcohol, acids, alkali and some disinfectants.11 
It is worth noting that practically all drugs used to treat tuberculosis are capable of causing toxic 
side effects.11 Therefore, it is obvious that new original drugs that are more active and effective 
than the existing ones are supposed to be discovered. In addition, pyrazinecarbonitrile analogs 
(pyrazinecarboxamide and pyrazine-2-carboxylic acid derivatives) are important and famous as 
the first-line antituberculosis drugs.11  
It is known that the addition reaction of 1,4-diazines and their benzo derivatives is of great 
importance for the synthesis of biologically active compounds, including alkaloids.12-17 In order 
to cause these transformations azaaromatic compounds are usually activated by quaternization to 
obtain N-alkyl-1,4-diazinium salts.17,18  Indeed, it has recently been shown that 1-alkyl-1,4-
diazinium cations are prone to add carbo- and heteroatomic nucleophiles to give mono- and 
diadducts, or to be transformed into condensed tetrahydropyrazines through the tandem addition 
reactions with bifunctional nucleophiles.17-26 On the other hand, the Petasis reaction is one of the 
multicomponent condensation reactions, which provides a convenient method for the preparation 
of α-amino acids by reacting an amine 1 with a carbonyl compound 2 and a boronic acid 3.27-34  
The reaction proceeds via the formation of aminal intermediate 4 (Scheme 1).  
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Scheme 1. The Petasis reaction with aryl boronic acid. 
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The reaction has also been applied to the synthesis of heterocyclic systems35-40 and solid 
phase synthesis of peptides.41-43 The reaction is a very efficient with alkenyl and electron-rich 
aromatic boronic acids. In addition to primary amines, the secondary amines, sterically hindered 
primary amines, and tertiary aromatic amines can also participate in these transformations. A 
mild, practical, and novel method for the C–C bond formation in the series of pyrazine 
(quinoxaline) derivatives by using the Petasis reaction has been developed through intermediacy 
of 6-alkoxy-1-ethyl-1,6-dihydropyrazines. All obtained dihydropyrazines were screened in vitro 
for their antimycobacterial activities against Mycobacterium tuberculosis H37Rv, avium, terrae 
and extensively drug-resistant and multi-drug-resistant  strains isolated from tuberculosis patients 
in Ural region (Russia). It has been found that some of these compounds exhibit a high 
tuberculostatic activity comparable with that of pyrazinamide. 
 
 
Results and Discussion    
 
We have earlier carried out a series of studies on the properties of substituted pyrazinium salts 
5a-c.22,23,44-50 It has been shown that they are capable of reacting with various types of 
nucleophiles under mild conditions to form products of nucleophilic addition to the unsubstituted 
positions of the pyrazine ring. The aim of the present study is to examine the further 
modifications of 6-alkoxy adducts 6-8 derived from the reaction of 5-(het)aryl-2,3-dicyano-1-
ethylpyrazinium tetrafluoroborates 5a-c with O-nucleophiles (water and alcohols) (Scheme 2).23 
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Scheme 2 
 
Taking into account a structural analogy between O-adducts 6-8 and amino alcohols 4 
derived from the Petasis reaction, we have investigated the reaction of 6-8 with thienylboronic 
acids. It has been established that the alkoxy adducts 6-8 react readily with 2-thienylboronic 9 
and 3-thienylboronic 10 acids under mild conditions (CH2Cl2, 20-25 °C, 1 hour) to give 1-ethyl-
5-(het)aryl-6-thiophen-2-yl-1,6-dihydropyrazine-2,3-dicarbonitriles 11a-c and 1-ethyl-5-
(het)aryl-6-thiophen-3-yl-1,6-dihydropyrazine-2,3-dicarbonitriles 12a-c (Scheme 3, Table 1). 
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Scheme 3 
 
In a similar way, the reaction of the hydroxy adducts 6a-c with benzo[b]thien-2-ylboronic 13 
and benzo[b]thien-3-ylboronic 14 acids leads to the corresponding 6-benzo[b]thiophen-2-yl-1-
ethyl-5-(het)aryl-1,6-dihydropyrazine-2,3-dicarbonitriles 15a-c and 6-benzo[b]thiophen-3-yl-1-
ethyl-5-(het)aryl-1,6-dihydropyrazine-2,3-dicarbonitriles 16a-c in good yields 55-98% (Scheme 
4, Table 1). 
N
NNC
NC
Ar
CH3
S
H
N
NNC
NC
Ar
CH3
OR
H
N
NNC
NC
Ar
CH3
S
H
S B(OH)2
S
B(OH)2
CH2Cl2
6a-c (R= H)
Ar =  a: Ph,  b: thiophen-2-yl, c: thiophen-3-yl
15a-c
16a-c
13
14
 
 
Scheme 4 
 
On treatment of the adducts 6a-c with 2-furanylboronic acid (17) the corresponding 1-ethyl-
6-furan-2-yl-5-(het)aryl-1,6-dihydropyrazine-2,3-dicarbonitriles 18a-c were obtained in yields 
55-98% (Scheme 5, Table 1). 
The evidence for the structures of all di(hetero)aryl-substituted dihydropyrazines has been 
obtained by means of 1H and 13C NMR spectroscopy, and X-ray crystallography analysis 
performed for racemic 1-ethyl-5-phenyl-6-thiophen-2-yl-1,6-dihydropyrazine-2,3-dicarbonitrile 
(11a), 1-ethyl-5-thiophen-3-yl-6-thiophen-2-yl-1,6-dihydro-pyrazine-2,3-dicarbonitrile (11c) and 
1-ethyl-5-phenyl-6-thiophen-3-yl-1,6-dihydropyrazine-2,3-dicarbonitriles (12a) (Figs. 1-3). 
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Figure 1. X-ray structure of  
(±)-11a. 
Figure 2. X-ray structure of 
(±)-11c. 
Figure 3. X-ray structure of 
(±)-12a. 
 
In case of highly reactive alkoxy adducts 6a, 7a and 8a yields of dihydropyrazine 11a are 
nearly independent of the substituents R in the alkoxy-group (see entries 1-3).  
The reactions of alkoxy adducts 6a-c,7a,8a with -rich heteroaromatic boronic acids proved 
to proceed in good yields (entries 1-17), however phenylboronic acid did not enter the reaction at 
all due to its low reactivity.51 It should be noted that the Petasis type reaction for 1,4-diazines is 
observed for the first time, although similar transformations have been described earlier for 
derivatives of quinoline and isoquinoline.51 
According to the X-ray data, all racemic compounds 11a,c and 12a are crystallized in 
centrosymmetric P21/n space group of monoclinic crystal system, and are characterized by the 
similarity of magnitudes in unit cell parameters (Tables 2, 4).  
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Table 1. Reaction conditions and yields of compounds 11, 12, 15, 16 and 18 
Entry Reaction Time, h Product 
Isolated 
yields (%) 
Yield on  
GC-MS (%) 
1 6a+9 1 11a 76 97 
2 7a+9 1 11a n.d. 98 
3 8a+9 1 11a n.d. 97 
4 6a+10 20 12a 57 n.d. 
5 6b+9 20 11b 68 n.d. 
6 6b+10 20 12b 64 n.d. 
7 6c+9 20 11c 65 n.d. 
8 6c+10 20 12c 79 n.d. 
9 6a+13 48 15a 55 n.d. 
10 6b+13 17 15b 58 n.d. 
11 6c+13 17 15c 98 n.d. 
12 6a+14 48 16a 59 n.d. 
13 6b+14 17 16b 76 n.d. 
14 6c+14 17 16c 80 n.d. 
15 6a+17 24 18a 75 n.d. 
16 6b+17 24 18b 86 n.d. 
17 6c+17 24 18c 71 n.d. 
n.d. – not determined 
 
Table 2. Some stereometric characteristics of dihydropyrazines according to the X-Ray data. A 
numeration of ring’s atoms is given according to the figure below 
N
N
Et
ArNC
NC Ar'
H
12
3
4
5
6
 
Compound (±)-11a (±)-11c (±)-12a 
d(С6-N1C2C3C4C5), Å.  0.408 0.499 0.394 
Dihedral angle 
C6N1C2C3/C3N4C5C6, deg. 
21.47 26.75 20.37 
Dihedral angle 
N1C2C3C4C5/C5C6N1, deg. 
27.59 33.96 26.45 
C6-C5, Å 1.518(2) 1.517(3) 1.533(3) 
C6-C(Ar’), Å 1.5066(19) 1.490(3) 1.499(3) 
C5-C(Ar), Å 1.4806(19) 1.455(3) 1.472(3) 
N1-C2, Å 1.3456(18) 1.348(3) 1.342(2) 
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Table 2. Continued 
С6-N1, Å 1.4769(18) 1.470(2) 1.472(2) 
Angle С5С6N1, deg. 109.89(12) 108.82(16) 109.79(18) 
C2-C(N), Å 1.446(2) 1.430(3) 1.442(3) 
C3-C(N), Å 1.429(2) 1.431(3) 1.432(3) 
(C2)C≡ (N), Å 1.1401(18) 1.139(3) 1.133(3) 
(C3)C≡ (N), Å 1.1431(18) 1.136(3) 1.141(2) 
 
Low variations in unit cell parameters for these structures are rationalised by the very similar 
packing requirements of the thiophene and benzene ring substituents in compounds 11a/12a and 
11c. The dihydropyrazine ring in compounds is non-planar, the sp3-hybridized atom is deviated 
from the least-squared plane of the ring on 0.4-0.5 Å, and dihedral angles between the planes 
C6N1C2C3 and C3N4C5C6 are in limits 20-30° (numeration of atoms is given according to the 
figure for Table 2). However, atoms C3, N4, C5 are placed approximately in the plane of 
(het)aryl substituent at C5 and the double C=N bond of the azadienic fragment is obviously 
conjugated with the π-electronic system of the substituent. Measured sterical parameters of the 
dihydropyrazinic system, in particular, deviation of the sp3-atom from a plane of the pyrazine 
ring d(С6-N1C2C3C4C5), dihedral angles between planes C6N1C2C3/C3N4C5C6 and 
N1C2C3C4C5/C5C6N1, are depending not from the type of substituents at the sp3-hybridised C-
atom (Ar'), but from effects of the dihydropyrazine azadiene system conjugation with Ar 
substituent at С5. For pair 11а/12а a good structural correspondence is observed, however at the 
same time the structural parameters for the pair 11а/11c show significant differences (see Table 
2). The next structural differences of dihydropyrazines are connected with their conformations 
and molecular packing. Dihedral angle between the plane of substitient Ar' at the sp3-hybridized 
C-atom and the plane C5C6C(Ar') for the pair 11а/12а  is ~50°, the same angle for compound 
11c is ~20° (exact definition of magnitudes is not possible due to disordering of substituent Ar'). 
Despite on proximity of unit cell parameters, molecular packing for the pair 11а/12а and 
compound 11c show some variations. In particular, molecular packing for the pair 11а/12а is 
characterized by the presence of π-contacts between C≡N-groups and the azadiene system of the 
dihydropirazinis ring with distance ~3.3Å. This type of interaction is absent in packing of 
compound 11c, and their molecules form layers parallel 0b axe by means of axial N…S type 
contacts with distances ~3.25 Å between C≡N-groups and S-atoms of thienyl substituent at C5. 
All dihydropyrazines (±)-11, 12, 15, 16 and 18  were separated as pure enantiomers 
[enantiomeric excess approximately 95-99.9%] by semi-preparative chiral HPLC using Kromasil 
5-CelluCoat (150 × 4.6 mm, 5 μm) column. Chiral HPLC and polarimetric analysis indicated 
that for all racemates, the first eluted enantiomers rotated polarized light in the negative 
direction, accordingly to a similar nature of substituents at the stereogenic center C(6). Crystals 
of enantiomeric pairs R-(-)-11b/S-(+)-11b and R-(-)-11c /S-(+)-11c suitable for X-ray 
experiments were grown by crystallization from acetonitrile solution. Enantiomeres R-(-)-11b/S-
(+)-11b and R-(-)-11c/S-(+)-11c were crystallized in very typical chiral P212121 space group of 
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orthorhombic crystal system with the nearest magnitudes in unit cell parameters (Tables 5, Figs. 
4 and 5). All deviations in magnitudes in unit cell parameters for the pair of enantiomeres can to 
be explained by variation in temperatures of experiments and experimental errors. The presence 
of sulfur atoms in their structures permits to establish an absolute configuration of compounds. 
The absolute configuration of compounds was established on the basis of anomalous scattering 
effect (by Flack parameters), however, only for the R-(-)-11b and S-(+)-11c isomers their 
parameters are significant (Table 5). For the isomers R-(+)-11b and S-(-)-11c their parameters 
are less than the measurement mistakes, but are in accordance with measurements for 
enantiopodes. General stereochemistry of the enantiomeres is in good agreement with the 
stereochemistry of racemates. Some variations in dihedral angles due to rotation of a substituent 
around the single C-C bond’s axis can to be explained by changing in the molecular packing 
environment. Any shortened intermolecular contacts in the molecular packing are absent. 
 
 
Figure 4. X-ray structure of enantiomer  
R-(-)-11b. 
Figure 5. X-ray structure of enantiomer  
S-(+)-11b. 
 
On the basis of combined chromatographic and X-ray studies, the absolute configuration 
assignment was unambiguously completed, and configurations were assigned to the fifteen 
enantiomeric pairs: R-(-)-11a-c, 12a-c, 15a-c, 16a-c, 18a-c/S-(+)-11a-c, 12a-c, 15a-c, 16a-c, 
18a-c. Due to comparable chiral centers in this group of molecules, the results clearly indicate at 
the (S)-absolute configuration for all dextrorotatory enantiomers of the series and at the (R)-
absolute configuration for the corresponding levorotatory isomers. 
The antimycobacterial activity of compounds 11, 12, 15, 16 and 18 was tested against M. 
tuberculosis H37Rv, avium, terrae and extensively drug-resistant and multi-drug-resistant strains. 
All new dihydropyrazines were compared with the commercially available drugs Isoniazid and 
Pyrazineamide under the same experimental conditions (Table 3). 
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Table 3. Antimycobacterial activity of 1,6-dihydropyrazines 
Entry Compound 
Antimycobacterial activity against different strains  
of Mycobacterium tuberculosis (MIC in μg/mL) 
H37Rv M. avium M. terrae MDR XDR 
1 R-(-)-11a 6.2 6.2 6.2 6.2 6.2 
2 S-(+)-11a 6.2 6.2 6.2 6.2 6.2 
3 R-(-)-11b 6.2 6.2 6.2 6.2 6.2 
4 S-(+)-11b 6.2 6.2 6.2 6.2 6.2 
5 R-(-)-11c 6.2 3.1 3.1 6.2 6.2 
6 S-(+)-11c 6.2 6.2 6.2 6.2 6.2 
7 R-(-)-12a 1.5 0.75 0.75 1.5 1.5 
8 S-(+)-12a 3.1 3.1 1.5 3.1 3.1 
9 R-(-)-12b 0.75 0.3 0.3 0.75 0.75 
10 S-(+)-12b 1.5 0.75 0.75 1.5 1.5 
11 R-(-)-12c 6.2 6.2 6.2 6.2 6.2 
12 S-(+)-12c 6.2 6.2 6.2 6.2 6.2 
13 R-(-)-15a 12.5 12.5 12.5 12.5 12.5 
14 S-(+)-15a 12.5 12.5 12.5 12.5 12.5 
15 R-(-)-15b 12.5 12.5 12.5 12.5 12.5 
16 S-(+)-15b 12.5 12.5 12.5 12.5 12.5 
17 R-(-)-15c 12.5 12.5 12.5 12.5 12.5 
18 S-(+)-15c 12.5 12.5 12.5 12.5 12.5 
19 R-(-)-16a 12.5 12.5 12.5 12.5 12.5 
20 S-(+)-16a 12.5 12.5 12.5 12.5 12.5 
21 R-(-)-16b 1.5 0.75 0.75 1.5 1.5 
22 S-(+)-16b 12.5 12.5 12.5 12.5 12.5 
23 R-(-)-16c 1.5 0.75 0.75 1.5 1.5 
24 S-(+)-16c 6.2 6.2 6.2 6.2 6.2 
25 R-(-)-18a 12.5 12.5 12.5 12.5 12.5 
26 S-(+)-18a 12.5 12.5 12.5 12.5 12.5 
27 R-(-)-18b 0.75 0.3 0.3 0.75 0.75 
28 S-(+)-18b 12.5 12.5 12.5 12.5 12.5 
29 R-(-)-18c 12.5 12.5 12.5 12.5 12.5 
30 S-(+)-18c 12.5 12.5 12.5 12.5 12.5 
 Pyrazinamide 12.5 n.d. n.d. - - 
 Isoniazid 0.1 0.1 0.1 - - 
n.d. – not determined; MDR (multi-drug-resistant tuberculosis strain) – Rifampin and isoniazid 
resistant Mycobacterium tuberculosis strain having Beijing genotype with a combination of 
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mutations Ser 531 - Leu 315 and Ser-Thr in rpoB and katG genes, respectively; XDR – 
extensively drug-resistant tuberculosis strain.  
 
It has been established that the most active compounds of the series contain thiophenyl 
groups, while a low activity was found for the phenyl-substituted dihydropyrazines. Compounds, 
bearing 3-thiophenyl 12a,b and 3-benzo[b]thiophenyl 16b,c fragments at C(6) position of the 
dihydropyrazine ring, were highly antimicobactrial and inhibited M. tuberculosis growth at 
concentration of 0.75-1.5 μg/mL. Incorporation of 2-thiophenyl 11a-c group at C(6) position of 
the dihydropyrazine ring resulted in a slightly less activity (MIC 6.2 μg/mL). In contrast, 
introduction of other groups, such as 2-benzo[b]thiophenyl (15a-c) or 2-furyl (18a,c), resulted in 
rather poor activity (MIC 12.5 μg/mL). Furthermore, the most active compounds exhibited 
enantiomer selectivity, generally preferring the R-(-)-forms over the S-(+)-enantiomers, as 
demonstrated by the data for compounds R-(-)-12a, R-(-)-12b, R-(-)-16b, R-(-)-16c and R-(-)-
18b (see Table 3). 
The results obtained show that antimycobacterial activity of several derivatives of the series 
of 1-alkyl-2,3-dicyano-5-aryl-6-hetaryl-1,6-dihydropyrazines is similar to the standard drugs. In 
addition, the compounds of this series are active against extensively drug-resistant and multi-
drug-resistant strains of Mycobacterium tuberculosis. 
 
 
Conclusions    
 
It has been shown that the Petasis reaction provides a mild, practical, and novel method for 
noncatalytic synthesis of dihydropyrazine derivatives. Novel 1-alkyl-2,3-dicyano-5-(het)aryl-6-
hetaryl-1,6-dihydropyrazines have been obtained and characterized. The structures of these 
compounds have been established by X-ray crystallography analysis. Several compounds of this 
series proved to possess a better antimycobacterial activity, than those from the family of classic 
antituberculosis drugs, for example Pyrazinamide. Indeed, 6-thienyl and 6-furyl substituted 1-
alkyl-2,3-dicyano-5-(het)aryl-6-hetaryl-1,6-dihydropyrazines can be regarded as promising 
candidates for the further development of antitubercular agents. 
    
  
Experimental Section     
 
General. All solvents and reagents were purified and prepared according to the literature data.52 
Compounds 6-8 were synthesized according to the procedures described in the literature.23 1H 
and 13C NMR spectra were recorded on a Bruker AVANCE-500 instrument using Me4Si as an 
internal standard. All signals in the 1H and 13C NMR spectra were assigned on the basis of 2D 
1H–1H COSY, 1H–13C HSQC and HMBC experiments. Elemental analysis was carried on a 
Eurovector EA 3000 automated analyzer. Melting points were determined on Boetius combined 
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heating stages and were not corrected. The GC-MS analysis of all samples was carried out using 
an Agilent GC 7890A MS 5975C Inert XL EI/CI GC-MS spectrometer with a quadrupole mass-
spectrometric detector with electron ionization (70 eV) and scan over the total ionic current in 
the range m/z 20–1000 and a quartz capillary column HP-5MS (30 m × 0.25 mm, film thickness 
0.25 mm). Helium was used as a carrier gas, the split ratio of the flow was 1 : 50, and the 
consumption through the column was 1.0 mL min–1; the initial temperature of the column was 40 
°C (storage 3 min), programming rate was 10 °C min–1 to 290 °C (storage 20 min), the 
temperature of the evaporator was 250 °C, the temperature of the source was 230 °C, the 
temperature of  the quadrupole was 150 °C, and the temperature of the transition chamber was 
280 °C. Solutions of the samples with a concentration of 3–4 mg mL–1 were prepared in 
acetonitrile. Samples of 1 mL of the obtained solutions were analyzed. Column chromatography 
was carried out using Lancaster silica gel 0.040–0.063 mm (230–400 mesh), eluting with ethyl 
acetate–hexane, 1 : 2. The progress of reactions and the purity of compounds were checked by 
TLC on Sorbfil plates (Russia), in which the spots were visualized with UV light (λ 254 or 365 
nm).  
Microwave experiments were carried out in a Discover unimodal microwave system (CEM, 
USA) with a working frequency of 2.45 GHz and the power of microwave radiation ranged from 
0 to 300 W. The reactions were carried out in a 10 mL reaction tube with the hermetic Teflon 
cork. The temperature of the reaction was monitored using an inserted IR sensor by the external 
surface of the reaction vessel.  
Semi-preparative HPLC enantioseparations were performed on an Agilent 1100 instrument using 
stainless-steel Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The analytical HPLC to 
determine the enantiomeric excess of the optically pure compounds was performed on the same 
instrument using chiral Kromasil CelluCoat (150 × 4.6 mm, 5 μm) column and mobile phase of 
CH3CN-H2O at the different ratio. The values of retention time (tR) were given in minutes. 
Enantiomeric excess values were calculated from peak areas using the formula (A1-
A2)/(A1+A2), where A1 is the major enantiomer. Specific rotations of enantiomers were 
measured at 589 nm with a Perkin-Elmer polarimeter model 341 equipped with a Na lamp. The 
volume of the cell was 1 mL, and the optical path was 10 cm. A standard solution was prepared 
by dissolving 5 mg of compound into 2 mL of CH3CN (c = 0.25). 
X-ray diffraction analysis of single crystals of 11a,c, 12a and R-(-)-11c was performed on an 
automated X-ray diffractometer “Xcalibur 3” equipped with CCD detector. Compounds R-(-)-
11b, S-(+)-11b, S-(+)-11c were analyzed on an automated X-ray diffractometer “Xcalibur E” on 
a standard procedure (λMoKα, graphite monochomator, ω/2θ scanning with step 1o). Empirical 
absorption correction was performed. Structures of compounds 11a,c, 12a and R-(-)-11c were 
solved and refined by full-matrix least-squared method on F2 with using SHELXTL program 
package.53 Compounds R-(-)-11b, S-(+)-11b, S-(+)-11c were solved and refined by using Olex2 
program.54 Non hydrogen atoms were refined in anisotropic approximation; H-atoms were 
refined in isotropic approximation in riding model. General X-Ray data are summarized in the 
Table 4. The X-ray crystallography data for structures 11a-c and 12a reported in this paper have 
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been deposited with Cambridge Crystallography Data Centre as supplementary publications no 
CCDC 991536 for (±)-11a, CCDC 991537 for (±)-11c, CCDC 991538 for (±)-12a, CCDC 
991532 for (+)-11b, CCDC 991533 for (-)-11b, CCDC 991534 for (+)-11c and CCDC 991535 
for (-)-11c. These data can be obtained free of charge from the Cambridge Crystallographic Data 
Centre via www.ccdc.cam.ac.uk/data_request/cif. 
 
Table 4. General X-ray structural data for racemic compounds 11a,c and 12a 
Compound 11a 11с 12a 
Crystal size, mm 0.25×0.20×0.15 0.25×0.20×0.15 0.25×0.20×0.15 
Crystal color Orange orange orange 
Empirical formula C18H14N4S C16H12N4S2 C18H14N4S 
Temperature, K 295(2) 295(2) 295(2) 
Crystal system Monoclinic Monoclinic Monoclinic 
Space group P21/n P21/n P21/n 
a, Å 10.1483(9) 8.1995(7) 10.1126(17) 
b, Å 16.0775(16) 16.8758(15) 15.9301(14) 
c, Å 10.3350(10) 12.2379(9) 10.2752(13) 
α 90 90 90 
β 107.086(8) 108.675(7) 107.097(13) 
γ 90 90 90 
Volume (Å), Z 1611.8(3), 4 1604.2(2), 4 1582.1(4), 4 
μ, mm-1 0.205 0.333 0.209 
Reflections  
collected 
10204 8088 5918 
Independent  
reflections(Rint) 
3958  
(0.0291) 
3862  
(0.0219) 
3157 (0.0311) 
Reflections  
with I>2σ(I) 
1615 1860 1354 
GooF 1.002 0.990 1.002 
R1 [I>2σ(I)] 0.0348 0.0455 0.0362 
wR2 [I>2σ(I)] 0.0710 0.1231 0.0492 
R1 (all data) 0.0995 0.0946 0.0951 
wR2 (all data) 0.0748 0.1334 0.0512 
Largest diff.  
peak and hole, ē/Å3 
0.145/-0.220 0.258/-0.300 0.167/-0.237 
Completeness  
to θ (deg.) 
98.9 %  
(28.28) 
98.8 %  
(26.00) 
97.5 %  
(26.38) 
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Table 5. General X-ray structural data for enantiomeric compounds R-(-)-11b /S-(+)-11b and R-
(-)-11c /S-(+)-11c 
Compound R-(-)-11b S-(+)-11b R-(-)-11c S-(+)-11c 
Crystal size, mm 0.26×0.21×0.17 0.23×0.17×0.08 0.30x0.25x0.20 0.25×0.2×0.15 
Crystal color orange orange orange orange 
Empirical formula C16H12N4S2 C16H12N4S2 C16 H12N4S2 C16H12N4S2 
Temperature, K 120.00(10) 150.0(1) 295(2) 149.91(18) 
Crystal system orthorhombic  orthorhombic  orthorhombic orthorhombic  
Space group P212121  P212121  P212121 P212121  
a, Å 7.2966(3)  7.30865(17)  7.3139(10) 7.24218(12)  
b, Å 12.5764(5)  12.6253(4)  12.8680(6) 12.7486(2)  
c, Å 17.2086(7)  17.2173(4)  17.0494(18) 17.0675(3)  
α 90  90.00  90.00 90.00  
β 90  90.00  90.00 90.00  
γ 90  90.00  90.00 90.00  
Volume (Å), Z 1579.15(11) 1588.71(7), 4 1604.6(3), 4 1575.80(4), 4 
μ, mm-1 0.338 0.336 0.333 0.339 
Reflections  
collected 
9187 7269  11930 10783 
Independent  
reflections(Rint) 
5200 (0.0295) 4330 (0.0237)  3981 (0.0376) 6291 (0.0196) 
Reflections  
with I>2σ(I) 4745 3980 1748 5655 
GooF 1.002 1.219 1.000 1.001 
R1 [I>2σ(I)] 0.0392 0.0369  0.0472 0.0386 
wR2 [I>2σ(I)] - 0.0905 0.0906 0.1084 
R1 (all data) 0.0458 0.0425 0.1053 0.0457 
wR2 (all data) 0.1021 0.1009 0.0945 0.1173 
Largest diff.  
peak and hole, ē/Å3 0.59/-0.28 0.46/-0.33 0.342/-206 0.47/-0.35 
Flack parameter    0.06(9) 0.07(6) 
Completeness  
to θ (deg.) 
  
99.9 % (28.30) 99.80 % (33.07) 
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General procedure for the synthesis of 5,6-disubstituted 1,6-dihydropyrazine derivatives 
(11,12,15,16 and 18). A mixture of compound 6 (7 or 8) (0.5 mmol) and hetero(aryl)boronic (2-
thienylboronic, 3-thienylboronic, benzo[b]thien-2-ylboronic, benzo[b]thien-3-ylboronic or 2-
furanylboronic) acid (0.6 mmol) was dissolved in 3 mL CH2Cl2. The resulting solution was 
stirred for an appropriate time (see Table 1) at room temperature, the solvent was distilled off in 
vacuo, and the residue was purified by flash column chromatography (hexane/ethyl acetate) to 
afford the desired di(hetero)aryl-substituted dihydropyrazine derivatives 11, 12, 15, 16 and 18. 
1-Ethyl-5-phenyl-6-thiophen-2-yl-1,6-dihydropyrazine-2,3-dicarbonitrile (11a). Yield of the 
racemate (see Table 1, entries 1-3), yellow-orange powder, mp 135-137 °C. Racemate was 
separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The 
eluent mixture CH3CN–H2O 65:35 was used in isocratic mode (0.6 mL/min at 25 ºC), and the 
UV signal was monitored at λ 268 nm to obtain the resolved enantiomeric pair R-(-)-11a/S-(-)-
11a (tR 7.37, tR 11.00). R-(-)-11a: [α]D20 -968 (c 0.25, CH3CN), ee 98.7% (Kromasil 5-CelluCoat, 
CH3CN–H2O 70:30, tR 3.93); S-(+)-11a: [α]D20 +877 (c 0.25, CH3CN), ee 97.4% (Kromasil 5-
CelluCoat, CH3CN–H2O 70:30, tR 5.48 min). δH (500 MHz, CDCl3) 1.34 (t, 3H, CH3, J 7.2 Hz), 
3.71 (dq, 1H, NCHB, J 14.5, 7.2 Hz), 3.76 (dq, 1H, NCHA, J 14.5, 7.2 Hz), 5.96 (s, 1H, H6), 6.92 
(dt, 1H, H3', J 3.6, 1.0 Hz), 6.96 (dd, 1H, H4', J 5.1, 3.6 Hz), 7.33 (dd, 1H, H5', J 5.1, 1.2 Hz), 
7.44 (m, 2H, Hm;), 7.49 (m, 1H, Hp), 7.90 (m, 2H, Ho). δC (126 MHz, CDCl3) 14.97 (CH3), 
48.33 (NCH2), 52.36 (C6), 110.47 (CN), 111.31 (CN), 115.99 (C3), 118.24 (C2), 127.39 (C5'), 
127.45 (C4'), 127.59 (C3'), 127.97 (Co), 129.01 (Cm), 131.93 (Cp), 133.70 (Ci), 136.68 (C2'), 
147.37 (C5). GC tR 28.85 min; MS m/z (rel intensity) 318 (M+, 100). Calcd. for C18H14N4S 
(318.40): C 67.90, H 4.43, N 17.60. Found C 68.30, H 4.50, N 17.85. 
1-Ethyl-5,6-dithiophen-2-yl-1,6-dihydropyrazine-2,3-dicarbonitrile (11b). Yield of the 
racemate (see Table 1, entry 5), orange powder, mp 124-126 °C. Racemate was separated by 
chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The eluent mixture 
CH3CN–H2O 75:25 was used in isocratic mode (20 mL/min at 25 ºC), and the UV signal was 
monitored at λ 280 nm to obtain the resolved enantiomeric pair R-(-)-11b/S-(-)-11b (tR 2.92, tR 
3.46). R-(-)-11b: [α]D20 -1673 (c 0.25, CH3CN), ee 99.9% (Kromasil 5-CelluCoat, CH3CN–H2O 
70:30, tR 5.10); S-(+)-11b: [α]D20 +1603 (c 0.25, CH3CN), ee 93.5% (Kromasil 5-CelluCoat, 
CH3CN–H2O 70:30, tR 6.32). δH (500 MHz, CDCl3) 1.34 (t, 3H, CH3, J 7.2 Hz), 3.68 (dq, 1H, 
NCHB, J 14.5, 7.2 Hz), 3.73 (dq, 1H, NCHA, J 14.5, 7.2 Hz), 5.88 (s, 1H, H6), 6.95-6.97 (m, 2H, 
H3' and H4'), 7.09 (dd, 1H, H4", J 5.1, 3.8 Hz), 7.31 (m, 1H, H5'), 7.47 (dd, 1H, H3", J 3.8, 1.1 
Hz), 7.56 (dd, 1H, H5", J 5.1, 1.1 Hz). δC (126 MHz, CDCl3) 14.72 (CH3), 48.27 (NCH2), 53.39 
(C6), 110.18 (CN), 111.34 (CN), 115.84 (C3), 118.21 (C2), 127.21, 127.28 and 127.41 (C3', C4' 
and C5'), 128.25 (C4"), 129.88 (C3"), 132.99 (C5"), 136.97 (C2'), 140.40 (C2"), 143.26 (C5). 
GC tR 29.38 min; MS m/z (rel intensity) 324 (M+, 100). Calcd. for C16H12N4S2 (324.43): C 59.24, 
H 3.73, N 17.27, S 19.77. Found C 59.42, H 3.65, N 16.97, S 19.96. 
1-Ethyl-5-thophen-3-yl-6-thophen-2-yl-1,6-dihydropyrazine-2,3-dicarbonitrile (11c). Yield 
of the racemate (see Table 1, entry 7), bright yellow powder, mp 113-114 °C. Racemate was 
separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The 
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eluent mixture CH3CN–H2O 65:35 was used in isocratic mode (0.8 mL/min at 25 ºC), and the 
UV signal was monitored at λ 268 nm to obtain the resolved enantiomeric pair R-(-)-11c/S-(-)-
11c (tR 4.67, tR 6.18). R-(-)-11c: [α]D20 -1001 (c 0.25, CH3CN), ee >99.9% (Kromasil 5-
CelluCoat, CH3CN–H2O 70:30, tR 4.67); S-(+)-11c: [α]D20 +907 (c 0.25, CH3CN), ee 94.2% 
(Kromasil 5-CelluCoat, CH3CN–H2O 70:30, tR 6.33). δH (500 MHz, CDCl3) 1.34 (t, 3H, CH3, J 
7.2 Hz), 3.68 (dq, 1H, NCHB, J 14.3, 7.2 Hz), 3.73 (dq, 1H, NCHA, J 14.3, 7.2), 5.82 (s, 1H, H6), 
6.93 (dm, 1H, H3', J 3.6 Hz), 6.97 (dd, 1H, H4', J 5.0, 3.6 Hz), 7.32 (dd, 1H, H5', J 5.0, 1.2 Hz), 
7.37 (dd, 1H, H4", J 5.1, 2.8 Hz), 7.64 (dd, 1H, H5", J 5.1, 1.2 Hz), 7.78 (dd, 1H, H2", J 2.8, 1.2 
Hz). δC (126 MHz, CDCl3) 14.80 (CH3), 48.18 (CH2), 53.44 (C6), 110.18 (CN), 111.34 (CN), 
116.05 (C3), 118.14 (C2), 127.09 (C5"), 127.21 (C4"), 127.29 (C3'), 127.32 (C5'), 127.47 (C4'), 
128.76 (C2"), 136.98 (C2'), 137.89 (C3"), 143.87 (C5). GC tR 29.28 min; MS m/z (rel intensity) 
324 (M+, 100). Calcd. for C16H12N4S2 (324.43): C 59.24, H 3.73, N 17.27, S 19.77. Found C 
59.45, H 3.62, N 16.95, S 19.98. 
1-Ethyl-5-phenyl-6-thiophen-3-yl-1,6-dihydropyrazine-2,3-dicarbonitrile (12a). Yield of the 
racemate (see Table 1, entry 4), dark yellow powder, mp 154-155 °C. Racemate was separated by 
chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The eluent mixture 
CH3CN–H2O 60:40 was used in isocratic mode (0.6 mL/min at 25 ºC), and the UV signal was 
monitored at λ 268 nm to obtain the resolved enantiomeric pair R-(-)-12a/S-(-)-12a (tR 9.44, tR 
13.97). R-(-)-12a: [α]D20 -927 (c 0.25, CH3CN), ee 99.7% (Kromasil 5-CelluCoat, CH3CN–H2O 
60:40, tR 6.05);  S-(+)-12a: [α]D20 +859 (c 0.25, CH3CN), ee 97.6% (Kromasil 5-CelluCoat, 
CH3CN–H2O 60:40, tR 9.00). δH (500 MHz, CDCl3) 1.31 (t, 3H, CH3, J 7.2 Hz), 3.68 (dq, 1H, 
NCHB, J 14.5, 7.2 Hz), 3.76 (dq, 1H, NCHA, J 14.5, 7.2 Hz), 5.82 (s, 1H, H6), 6.98 (dd, 1H, H5', 
J 5.1, 1.4 Hz), 7.14 (ddd, 1H, H2', J 2.9, 1.4, 0.8 Hz), 7.36 (dd, 1H, H4', J 5.1, 2.9), 7.44 (m, 2H, 
Hm), 7.49 (m, 1H, Hp), 7.89 (m, 2H, Ho). δC (126 MHz, CDCl3) 15.11 (CH3), 48.60 (NCH2), 
52.83 (C6), 110.21 (CN), 111.41 (CN), 116.12 (C3), 118.37 (C2), 124.71 (C2'), 125.70 (C5'), 
127.92 (Co), 128.06 (C4'), 129.01 (Cm), 131.85 (Cp), 133.95 (Ci), 135.44 (C3'), 147.78 (C5). 
GC tR 29.10 min; MS m/z (rel intensity) 318 (M+, 100). Calcd. for C18H14N4S (318.40): C 67.90, 
H 4.43, N 17.60. Found C 68.05, H 4.65, N 17.55. 
1-Ethyl-5-thiophen-2-yl-6-thiophen-3-yl-1,6-dihydropyrazine-2,3-dicarbonitrile (12b). Yield 
of the racemate (see Table 1, entry 6), bright yellow powder, mp 141-143 °C. Racemate was 
separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The 
eluent mixture CH3CN–H2O 65:35 was used in isocratic mode (20 mL/min at 25 ºC), and the UV 
signal was monitored at λ 280 nm to obtain the resolved enantiomeric pair R-(-)-12b/S-(-)-12b 
(tR 3.42, tR 4.36). R-(-)-12b: [α]D20 -1475 (c 0.25, CH3CN), ee >99.9% (Kromasil 5-CelluCoat, 
CH3CN–H2O 60:40, tR 5.68);  S-(+)-12b: [α]D20 +907 (c 0.25, CH3CN), ee 93.5% (Kromasil 5-
CelluCoat, CH3CN–H2O 60:40, tR 7.32). δH (500 MHz, CDCl3) 1.31 (t, 3H, CH3, J 7.2 Hz), 3.65 
(dq, 1H, NCHB, J 14.5, 7.2 Hz), 3.73 (dq, 1H, NCHA, J 14.5, 7.2 Hz), 5.72 (s, 1H, H6), 6.98 (dd, 
1H, H5', J 5.1, 1.4 Hz), 7.09 (dd, 1H, H4", J 5.1, 3.8 Hz), 7.18 (ddd, 1H, H2', J 2.9, 1.4, 0.7 Hz), 
7.36 (dd, 1H, H4', J 5.1, 2.9 Hz), 7.45 (dd, 1H, H3", J 3.8, 1.1 Hz), 7.56 (dd, 1H, H5", J 5.1, 1.1 
Hz). δC (126 MHz, CDCl3): 14.82 (CH3), 48.49 (CH2), 53.88 (C6), 109.89 (CN), 111.43 (CN), 
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115.96 (C3), 118.37 (C2), 124.32 (C2'), 125.65 (C5'), 128.09 (C4'), 128.21 (C4"), 129.69 (C3"), 
132.85 (C5"), 135.70 (C3'), 140.75 (C2"), 143.50 (C5). GC tR 29.63 min; MS m/z (rel intensity) 
324 (M+, 100). Calcd. For C16H12N4S2 (324.43): C 59.24, H 3.73, N 17.27, S 19.77. Found C 
59.36, H 3.54, N 17.18, S 19.92. 
1-Ethyl-5,6-dithiophen-3-yl-1,6-dihydropyrazine-2,3-dicarbonitrile (12c). Yield of the 
racemate (see Table 1, entry 8), bright yellow powder, mp 113-114 °C. Racemate was separated 
by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The eluent mixture 
CH3CN–H2O 65:35 was used in isocratic mode (0.8 mL/min at 25 ºC), and the UV signal was 
monitored at λ 270 nm to obtain the resolved enantiomeric pair R-(-)-12c/S-(-)-12c (tR 5.08, tR 
6.60). R-(-)-12c: [α]D20 -992 (c 0.25, CH3CN), ee >99.9% (Kromasil 5-CelluCoat, CH3CN–H2O 
65:35, tR 4.61);  S-(+)-12c: [α]D20 +967 (c 0.25, CH3CN), ee 95.2% (Kromasil 5-CelluCoat, 
CH3CN–H2O 65:35, tR 6.23). δH (500 MHz, CDCl3) 1.31 (t, 3H, CH3, J 7.3 Hz), 3.65 (dq, 1H, 
NCHB, J 14.5, 7.3 Hz), 3.73 (dq, 1H, NCHA, J 14.5, 7.3 Hz), 5.67 (s, 1H, H6), 6.97 (dd, 1H, H5', 
J 5.1, 1.4 Hz), 7.16 (ddd, 1H, H2', J 2.9, 1.4, 0.7 Hz), 7.36 (dd, 1H, H4', J 5.1, 2.9 Hz), 7.37 (dd, 
1H, H4", J 5.1, 2.9 Hz), 7.64 (dd, 1H, H5", J 5.1, 1.3 Hz), 7.75 (dd, 1H, H2", J 2.9, 1.3 Hz). δC 
(126 MHz, CDCl3) 14.90 (CH3), 48.42 (CH2), 53.95 (C6), 109.90 (CN), 111.44 (CN), 116.17 
(C3), 118.28 (C2), 124.38 (C2'), 125.68 (C5'), 127.12 (C5"), 127.19 (C4"), 128.13 (C4'), 128.52 
(C2"), 135.74 (C3'), 138.21 (C3"), 144.19 (C5). GC tR 29.59 min; MS m/z (rel intensity) 324 
(M+, 100). Calcd. for C16H12N4S2 (324.43): C 59.24, H 3.73, N 17.27, S 19.77. Found C 58.98, H 
3.40, N 17.39, S 20.23. 
6-Benzo[b]thiophen-2-yl-1-ethyl-5-phenyl-1,6-dihydropyrazine-2,3-dicarbonitrile (15a). 
Yield of the racemate (see Table 1, entry 9), bright yellow powder, mp 68-70 °C. Racemate was 
separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The 
eluent mixture CH3CN–H2O 75:25 was used in isocratic mode (0.6 mL/min at 25 ºC), and the 
UV signal was monitored at λ 265 nm to obtain the resolved enantiomeric pair R-(-)-15a/S-(-)-
15a (tR 6.94, tR 10.51). R-(-)-15a: [α]D20 -955 (c 0.25, CH3CN), ee >99.9% (Kromasil 5-
CelluCoat, CH3CN–H2O 70:30, tR 4.67); S-(+)-15a: [α]D20 +918 (c 0.25, CH3CN), ee 94.2% 
(Kromasil 5-CelluCoat, CH3CN–H2O 70:30, tR 6.33). δH (500 MHz, CDCl3) 1.38 (t, 3H, CH3, J 
7.2 Hz), 3.75 (dq, 1H, NCHB, J 14.5, 7.2 Hz), 3.82 (dq, 1H, NCHA, J 14.5, 7.2 Hz), 6.02 (d, 1H, 
H6, J 0.8 Hz), 7.11 (s, 1H, H3'), 7.34-7.38 (m, 2H, H5',6'), 7.46 (m, 2H, Hm), 7.51 (t, 1H, Hp, J 
7.2, 1.4 Hz), 7.70 (m, 1H, H4'), 7.79 (m, 1H, H7'), 7.95 (dd, 2H, Ho, J 8.4, 1.3 Hz). δC (126 
MHz, CDCl3) 15.10 (CH3), 48.72 (NCH2), 53.18 (C6), 110.88 (CN), 111.24 (CN), 115.87 (C3), 
118.21 (C2), 122.41 (C7'), 124.20 (C4'), 124.56 (C3'), 125.04 and 125.62 (C5' and C6'), 128.04 
(Co), 129.10 (Cm), 132.09 (Cp), 133.66 (Ci), 136.94 (C2'), 138.68 (C3'a), 139.79 (C7'a), 146.99 
(C5). GC tR 36.22 min; MS m/z (rel intensity) 368 (M+, 100). Calcd. for C22H16N4S (368.46): C 
71.72, H 4.38, N 15.21. Found C 71.68, H 4.44, N 15.48. 
6-Benzo[b]thiophen-2-yl-1-ethyl-5-thiophen-2-yl-1,6-dihydropyrazine-2,3-dicarbonitrile 
(15b). Yield of the racemate (see Table 1, entry 10), dark yellow powder, mp 77-79 °C.  
Racemate was separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) 
column. The eluent mixture CH3CN–H2O 80:20 was used in isocratic mode (20 mL/min at 25 
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ºC), and the UV signal was monitored at λ 280 nm to obtain the resolved enantiomeric pair R-(-)-
15b/S-(-)-15b (tR 3.41, tR 4.21). R-(-)-15b: [α]D20 -1615 (c 0.25, CH3CN), ee >99.9% (Kromasil 
5-CelluCoat, CH3CN–H2O 70:30, tR 4.67); S-(+)-15b: [α]D20 +1578 (c 0.25, CH3CN), ee 94.2% 
(Kromasil 5-CelluCoat, CH3CN–H2O 70:30, tR 6.33). δH (500 MHz, CDCl3) 1.37 (t, 3H, CH3, J 
7.2 Hz), 3.72 (dq, 1H, NCHB, J 14.5, 7.2 Hz), 3.78 (dq, 1H, NCHA, J 14.5, 7.2 Hz), 5.92 (s, 1H, 
H6), 7.11 (dd, 1H, H4", J 5.0, 3.9 Hz), 7.15 (s, 1H, H3'), 7.34-7.39 (m, 2H, H5',6'), 7.52 (dd, 1H, 
H3", J 3.9, 1.0 Hz), 7.59 (dd, 1H, H5", J 5.0, 1.0 Hz), 7.72 (m, 1H, H4'), 7.78 (m, 1H, H7'). δC 
(126 MHz, CDCl3) 14.84 (CH3), 48.63 (NCH2), 110.68 (CN), 111.28 (CN), 115.67 (C3), 118.17 
(C2), 122.43 (C7'), 124.09 (C3'), 124.19 (C4'), 125.07 (C6'), 125.63 (C5'), 128.30 (C4"), 129.95 
(C3"), 133.24 (C5"), 137.17 (C2'), 138.66 (C3'a), 139.74 (C7'a), 140.44 (C2"), 142.74 (C5). GC 
tR 37.35 min; MS m/z (rel intensity) 374 (M+, 100). Calcd. for C20H14N4S2 (374.49): C 64.15, H 
3.77, N 14.96. Found C 63.91, H 3.56, N 15.02. 
6-Benzo[b]thiophen-2-yl-1-ethyl-5-thiophen-3-yl-1,6-dihydropyrazine-2,3-dicarbonitrile 
(15c). Yield of the racemate (see Table 1, entry 11), dark yellow powder, mp 75-77 °C. 
Racemate was separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) 
column. The eluent mixture CH3CN–H2O 65:35 was used in isocratic mode (0.8 mL/min at 25 
ºC), and the UV signal was monitored at λ 265 nm to obtain the resolved enantiomeric pair R-(-)-
15c/S-(-)-15c (tR 10.36, tR 13.55). R-(-)-15c: [α]D20 -1026 (c 0.25, CH3CN), ee >99.9% 
(Kromasil 5-CelluCoat, CH3CN–H2O 70:30, tR 4.67); S-(+)-15c: [α]D20 +830 (c 0.25, CH3CN), 
ee 94.2% (Kromasil 5-CelluCoat, CH3CN–H2O 70:30, tR 6.33). δH (500 MHz, CDCl3) 1.37 (t, 
3H, CH3, J 7.2 Hz), 3.72 (dq, 1H, NCHB, J 14.5, 7.2 Hz), 3.79 (dq, 1H, NCHA, J 14.5, 7.2 Hz), 
5.87 (s, 1H, H6), 7.13 (s, 1H, H3'), 7.35-7.39 (m, 2H, H5',6'), 7.39 (dd, 1H, H5", J 5.1, 2.8 Hz), 
7.68 (dd, 1H, H4", J 5.1, 1.4 Hz), 7.72 (m, 1H, H4'), 7.78 (m, 1H, H7'), 7.84 (dd, 1H, H2", J 2.8, 
1.4 Hz). δC (126 MHz, CDCl3) 14.92 (CH3), 48.56 (NCH2), 54.27 (C6), 110.60 (CN), 111.28 
(CN), 115.92 (C3), 118.10 (C2), 122.43 (C7'), 124.17 and 124.19 (C3' and C4'), 125.08 and 
125.62 (C5' and C6'), 127.12 (C4"), 127.39 (C5"), 128.91 (C2"), 137.20 (C2'), 137.91 (C3"), 
138.70 (C3'a), 139.75 (C7'a), 143.40 (C5). GC tR 37.36 min; MS m/z (rel intensity) 374 (M+, 
100). Calcd. for C20H14N4S2 (374.49): C 64.15, H 3.77, N 14.96. Found C 64.08, H 3.77, N 
14.70. 
6-Benzo[b]thiophen-3-yl-1-ethyl-5-phenyl-1,6-dihydropyrazine-2,3-dicarbonitrile (16a). 
Yield of the racemate (see Table 1, entry 12), yellow powder, mp 174-176 °C. Racemate was 
separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The 
eluent mixture CH3CN–H2O 75:25 was used in isocratic mode (0.6 mL/min at 25 ºC), and the 
UV signal was monitored at λ 265 nm to obtain the resolved enantiomeric pair R-(-)-16a/S-(-)-
16a (tR 6.18, tR 8.79). R-(-)-16a: [α]D20 -751 (c 0.25, CH3CN), ee >99.9% (Kromasil 5-
CelluCoat, CH3CN–H2O 70:30, tR 4.67); S-(+)-16a: [α]D20 +776 (c 0.25, CH3CN), ee 94.2% 
(Kromasil 5-CelluCoat, CH3CN–H2O 70:30, tR 6.33). δH (500 MHz, CDCl3) 1.28 (t, 3H, CH3, J 
7.2 Hz), 3.70 (dq, 1H, NCHB, J 14.4, 7.2 Hz), 3.83 (dq, 1H, NCHA, J 14.4, 7.2 Hz), 6.08 (s, 1H, 
H6), 7.27 (s, 1H, H2'), 7.38 (dd, 1H, Hm, J 8.3, 7.2 Hz), 7.45 (tt, 1H, Hp, J 7.2, 1.2 Hz), 7.48 
(ddd, 1H, H6', J 8.2, 7.1, 1.0 Hz), 7.56 (ddd, 1H, H5', J 8.1, 7.2, 1.0 Hz), 7.81 (m, 2H, Ho),. δC 
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(126 MHz, CDCl3) 15.05 (CH3), 49.14 (NCH2), 51.02 (C6), 110.70 (CN), 111.35 (CN), 116.14 
(C3), 118.06 (C2), 120.39 (C4'), 123.66 (C7'), 125.20 (C6'), 125.28 (C5'), 127.80 (Co), 128.99 
(Cm), 129,16 (С2э)б 129.20 (С3'), 131.95 (Cp), 133.72 (Ci), 136.25 (C3'a), 140.99 (C7'a), 
148.03 (C5). GC tR 35.29 min; MS m/z (rel intensity) 368 (M+, 100). Calcd. for C22H16N4S 
(368.46): C 71.72, H 4.38, N 15.21. Found C 71.63, H 4.29, N 15.39. 
6-Benzo[b]thiophen-3-yl-1-ethyl-5-thiophen-2-yl-1,6-dihydropyrazine-2,3-dicarbonitrile 
(16b). Yield of the racemate (see Table 1, entry 13), yellow powder, mp 224-226 °C (decomp.). 
Racemate was separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) 
column. The eluent mixture CH3CN–H2O 80:20 was used in isocratic mode (20 mL/min at 25 
ºC), and the UV signal was monitored at λ 227 nm to obtain the resolved enantiomeric pair R-(-)-
16b/S-(-)-16b (tR 3.12, tR 4.18). R-(-)-16b: [α]D20 -1035 (c 0.25, CH3CN), ee >99.9% (Kromasil 
5-CelluCoat, CH3CN–H2O 75:25, tR 6.32); S-(+)-16b: [α]D20 +941 (c 0.25, CH3CN), ee 98.1% 
(Kromasil 5-CelluCoat, CH3CN–H2O 75:25, tR 7.58). δH (500 MHz, CDCl3) 1.28 (t, 3H, CH3, J 
7.2 Hz), 3.65 (dq, 1H, NCHB, J 14.4, 7.2 Hz), 3.77 (dq, 1H, NCHA, J 14.4, 7.2 Hz), 6.00 (s, 1H, 
H6), 6.99 (dd, 1H, H4", J 5.0, 3.9 Hz), 7.29 (dd, 1H, H3", J 3.9, 1.0 Hz), 7.35 (s, 1H, H2'), 7.47 
(ddd, 1H, H6', J 8.2, 7.1, 1.0 Hz), 7.56 (ddd, 1H, H5', J 8.1, 7.1, 1.0 Hz), 7.91-7.94 (m, 2H, 
H4',7'). δC (126 MHz, CDCl3) 14.64 (CH3), 48.85 (NCH2), 51.73 (C6), 110.05 (CN), 111.37 
(CN), 115.99 (C3), 118.19 (C2), 120.24 (C4'), 123.65 (C7'), 125.22 (C6'), 125.36 (C5'), 128.19 
(C4"), 128.67 (C2'), 129.48 (C3"), 130.07 (C2'), 132.81 (C5"), 136.41 (C3'a), 140.48 (C2"), 
140.79 (C7'a), 143.98 (C5). GC tR 36.61 min; MS m/z (rel intensity) 374 (M+, 100). Calcd. for 
C20H14N4S2 (374.49): C 64.15, H 3.77, N 14.96. Found C 63.91, H 3.56, N 15.02. 
6-Benzo[b]thiophen-3-yl-1-ethyl-5-thiophen-3-yl-1,6-dihydropyrazine-2,3-dicarbonitrile 
(16c). Yield of the racemate (see Table 1, entry 14), yellow powder, mp 227-228 °C. Racemate 
was separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The 
eluent mixture CH3CN–H2O 80:20 was used in isocratic mode (20 mL/min at 25 ºC), and the UV 
signal was monitored at λ 266 nm to obtain the resolved enantiomeric pair R-(-)-16c/S-(-)-16c (tR 
3.34, tR 5.20). R-(-)-16c: [α]D20 -684 (c 0.25, CH3CN), ee 99.3% (Kromasil 5-CelluCoat, 
CH3CN–H2O 75:25, tR 5.68); S-(+)-16c: [α]D20 +679 (c 0.25, CH3CN), ee 98.4% (Kromasil 5-
CelluCoat, CH3CN–H2O 75:25, tR 9.31). δH (500 MHz, CDCl3) 1.28 (t, 3H, CH3, J 7.2 Hz), 3.65 
(dq, 1H, NCHB, J 14.4, 7.2 Hz), 3.77 (dq, 1H, NCHA, J 14.4, 7.2 Hz), 5.94 (s, 1H, H6), 7.32 (s, 
1H, H2'), 7.33 (dd, 1H, H5", J 5.0, 2.9 Hz), 7.47 (ddd, 1H, H6', J 8.2, 7.1, 1.0 Hz), 7.56 (ddd, 
1H, H5', J 8.1, 7.1, 1.0 Hz), 7.60-7.62 (m, 2H, H4",2"), 7.91-7.95 (m, 2H, H4',7'). δC (126 MHz, 
CDCl3) 14.75 (CH3), 48.82 (NCH2), 51.80 (C6), 110.05 (CN), 111.37 (CN), 116.22 (C3), 118.14 
(C2), 120.16 (C4'), 123.70 (C7'), 125.23 (C6'), 125.38 (C5'), 126.95 (C4"), 127.14 (C5"), 128.44 
(C2"), 128.86 (C2'), 130.02 (C3'), 136.43 (C3'a), 137.97 (C3"), 140.88 (C7'a), 144.63 (C5). GC 
tR 36.40 min; MS m/z (rel intensity) 374 (M+, 100). Calcd. for C20H14N4S2 (374.49): C 64.15, H 
3.77, N 14.96. Found C 64.12, H 3.83, N 14.96. 
1-Ethyl-6-furan-2-yl-5-phenyl-1,6-dihydropyrazine-2,3-dicarbonitrile (18a). Yield of the 
racemate (see Table 1, entry 15), yellow-orange powder, mp 137-140 °C. Racemate was 
separated by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The 
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eluent mixture CH3CN–H2O 65:35 was used in isocratic mode (0.6 mL/min at 25 ºC), and the 
UV signal was monitored at λ 270 nm to obtain the resolved enantiomeric pair R-(-)-18a/S-(-)-
18a (tR 6.32, tR 9.35). R-(-)-18a: [α]D20 -1032 (c 0.25, CH3CN), ee 96.7% (Kromasil 5-CelluCoat, 
CH3CN–H2O 65:35, tR 5.53); S-(+)-18a: [α]D20 +945 (c 0.25, CH3CN), ee 96.6% (Kromasil 5-
CelluCoat, CH3CN–H2O 65:35, tR 7.96 min). δH (500 MHz, CDCl3) 1.36 (t, 3H, CH3, J 7.2 Hz), 
3.69 (dq, 1H, NCHA, J 14.5, 7.2 Hz), 3.79 (dq, 1H, NCHB, J 14.5, 7.2 Hz), 5.82 (s, 1H, H6), 6.19 
(d, 1H, H4', J 3.2 Hz), 6.32 (dd, 1H, H5', J 3.2, 1.8 Hz), 7.43-7.51 (m, 4H, H3' and Ph), 7.86-
7.87 (m, 2H, Ph). δC (126 MHz, CDCl3) 14.71 (CH3), 48.82 (NCH2), 50.84 (C6), 110.07, 111.03, 
111.07, 111.30, 116.10, 118.23, 127.83, 128.96, 131.87, 133.72, 144.20, 145.29, 147.35. GC tR 
27.04 min; MS m/z (rel intensity) 302 (M+, 100). Calcd. for C18H14N4O (302.34): C 71.51, H 
4.67, N 18.53. Found C 71.30 , H 4.48, N 18.75. 
1-Ethyl-6-furan-2-yl-5-thiophen-2-yl-1,6-dihydropyrazine-2,3-dicarbonitrile(18b). Yield of 
the racemate (see Table 1, entry 16), yellow powder, mp 102-105 °C. Racemate was separated 
by chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The eluent mixture 
CH3CN–H2O 65:35 was used in isocratic mode (20 mL/min at 25 ºC), and the UV signal was 
monitored at λ 280 nm to obtain the resolved enantiomeric pair R-(-)-18b/S-(-)-18b (tR 5.75, tR 
7.10). R-(-)-18b: [α]D20 -906 (c 0.25, CH3CN), ee 88.5% (Kromasil 5-CelluCoat, CH3CN–H2O 
65:35, tR 5.27); S-(+)-18b: [α]D20 +1721 (c 0.25, CH3CN), ee 95.2% (Kromasil 5-CelluCoat, 
CH3CN–H2O 65:35, tR 6.42). δH (500 MHz, CDCl3) 1.34 (t, 3H, CH3, J 7.2 Hz), 3.67 (dq, 1H, 
NCHA, J 14.5, 7.2 Hz), 3.74 (dq, 1H, NCHB, J 14.5, 7.2 Hz), 5.72 (s, 1H, H6), 6.23 (d, 1H, H4', J 
3.4 Hz), 6.33 (dd, 1H, H5', J 3.4, 1.8 Hz), 7.09 (dd, 1H, H4", J 5.0, 3.8 Hz), 7.42-7.43 (m, 2H, 
H3' and H3"), 7.56 (dd, 1H, H5", J 5.0, 1.0). δC (126 MHz, CDCl3) 14.46 (CH3), 48.65 (NCH2), 
51.74 (C6), 109.85, 110.47, 111.03, 111.34, 115.92, 118.26, 128.19, 129.71, 132.82,  140.47, 
141.29, 144.09, 147.35. GC tR 27.42 min; MS m/z (rel intensity) 308 (M+, 100). Calcd. for 
C16H12N4OS (308.36): C 62.32, H 3.92, N 18.17. Found C 62.22, H 3.77, N 18.45. 
1-Ethyl-6-furan-2-yl-5-thophen-3-yl-1,6-dihydropyrazine-2,3-dicarbonitrile (18c). Yield of 
the racemate (see Table 1, entry 17), yellow powder, mp 103-106 °C. Racemate was separated by 
chiral HPLC with a Kromasil 5-CelluCoat (150 × 4.6 mm, 5 μm) column. The eluent mixture 
CH3CN–H2O 60:40 was used in isocratic mode (0.8 mL/min at 25 ºC), and the UV signal was 
monitored at λ 270 nm to obtain the resolved enantiomeric pair R-(-)-18c/S-(-)-18c (tR 5.58, tR 
7.62). R-(-)-18c: [α]D20 -1112 (c 0.25, CH3CN), ee 99.6% (Kromasil 5-CelluCoat, CH3CN–H2O 
60:40, tR 6.60); S-(+)-18c: [α]D20 +982 (c 0.25, CH3CN), ee 93.0% (Kromasil 5-CelluCoat, 
CH3CN–H2O 60:40, tR 8.93). δH (500 MHz, CDCl3) 1.34 (t, 3H, CH3, J 7.2 Hz), 3.67 (dq, 1H, 
NCHA, J 14.5, 7.2 Hz), 3.74 (dq, 1H, NCHB, J 14.5, 7.2), 5.67 (s, 1H, H6), 6.21 (d, 1H, H3', J 
3.3), 6.33 (dd, 1H, H4', J 3.3, 1.8 Hz), 7.37 (dd, 1H, H5", J 5.2, 2.8 Hz), 7.43 (dd, 1H, H5', J 1.8, 
0.7 Hz), 7.63 (dd, 1H, H4", J 5.2, 1.3 Hz), 7.75 (dd, 1H, H2", J 2.8, 1.3 Hz). δC (126 MHz, 
CDCl3) 14.54 (CH3), 48.61 (CH2), 51.85 (C6), 109.79, 110.59, 111.06, 111.35, 116.16, 118.16, 
126.96, 127.13, 128.59, 137.93, 141.93, 144.08, 147.44. GC tR 27.43 min; MS m/z (rel intensity) 
308 (M+, 100). Calcd. for C16H12N4OS (308.36): C 62.32, H 3.92, N 18.17. Found C 62.12, H 
3.76, N 18.44. 
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Antimycobacterial assay. To evaluate the inhibitory efficiency of molecules on Mycobacterium 
tuberculosis, M. tuberculosis H37Rv, which is susceptible to all classical antituberculosis drugs, 
was used. The minimal inhibitory concentration (MIC) for M. tuberculosis H37Rv for each 
compound was determined by a micro broth dilution method. All molecules tested were 
dissolved in dimethylsulfoxide and their 1/2 dilutions were prepared in 5 mL tubes using 
Löwenstein-Jensen medium. A few colonies from freshly grown M. tuberculosis H37Rv were 
suspended in Löwenstein-Jensen medium to obtain 1.0 McFarland turbidity and diluted ten times 
using the same medium and the tubes were incubated at 37 °C medium with a different 
concentration of the tested molecule and to a positive control tube containing only clear growth 
medium. After 24 hours the tubes were placed in a vertical position and the free edge of the 
buried 0.3 mL of the substance in the test compounds concentrations: 12.5, 6.2, 3.1, 1.5, 0.75 
μg/mL. The tubes were then placed in an thermostat at a temperature of 37 °C and incubated for 
10 days. Growth estimate for the MTB were determined by standard methods, where the 
appearance of zones of growth retardation MTB (over 10 mm) indicated the presence of 
tuberculostatic properties in concentration of the compounds under study. Penetration size 
stunting MTB (in mm) is proportional to the degree of tuberculostatic activity. Growth delay of 
100 mm or more is considered as a complete growth inhibition MTB. The extensively drug-
resistant (XDR) and multi-drug-resistant (MDR) tuberculosis strains have been isolated from 
tuberculosis patients in Ural Research Institute for Phthisiopulmonology (Russia). The minimal 
inhibitory concentrations against Mycobacterium tuberculosis avium, Mycobacterium 
tuberculosis terrae, XDR and MDR tuberculosis strains were evaluated similarly. 
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